Patent Application
20080089944
Turning to the drawings, in greater detail, and initially to
In one embodiment, the chamber 12 is an upright metallic vessel of appropriate volume (e.g., 6 L) having two viewing windows (not shown). The chamber also includes an internal shelf 20 adapted to hold a plurality of containers or vials 22. Additionally, a stoppering mechanism 24 is situated above shelf 20 for purposes to be described. The device 14 includes an external ultrasonic transducer 26 operably coupled with a probe 28 within chamber 12.
The antisolvent system 16 includes a gas cylinder 30 designed to hold a supply of antisolvent gas, with a line 32 having valves 34 and 36 and moisture trap 38 interposed therein. As shown, the line 32 intersects an outlet conduit 40 leading from chamber 12. A bypass line 42 extends from valve 34 to the bottom of chamber 12, and a delivery line 44 extends from valve 36 to booster pump 46; the line 44 is also equipped with a filter 48 and a pressure indicator 50. The output from pump 46 is delivered via line 52 having a 4.5 L surge tank 54, valve 56, and temperature and pressure indicators 58 and 60 therein. As shown, the line 52 is coupled with the base of chamber 12 for delivery of antisolvent gas into the chamber. An air line 62 having valve 64 therein is also coupled with pump 46.
A safety valve 66 is operably coupled with conduit 40 and has a vent 68. Pressure and temperature indicators 70 and 72 are respectively coupled with conduit 40 and chamber 12.
The system 18 is optional and comprises a gas cylinder 74 coupled with a line 76 having a valve 78 therein. The cylinder 74 normally holds a supply of nitrogen which is used to test the leak integrity of the chamber 12 and associated components, prior to actual use thereof.
The containers 22 are entirely conventional and for purposes of illustration are shown with open mouths 80, and stoppers 82 loosely fitted within the mouths 80 so that the interior of the containers communicate with the atmosphere within chamber 12. As shown, each valve contains a quantity 84 of a liquid solution or dispersion having therein the material to be precipitated. After precipitation (
The stoppering device 24 is schematically illustrated and contains a common header 88 with a series of depending, reciprocal plungers 90 respectively situated above each stopper 82. The plungers 90 are operable to engage the respective stoppers 82 to fully seat the latter within the container mouths 80 as illustrated in
During use of apparatus 10, the latter is first heated to a specified temperature using a conventional heating tap coupled with a controller (not shown). The entire system is then tested for leakage using nitrogen system 18. Following testing, a plurality of containers 22 each having a quantity 84 of the liquid solution or dispersion are placed on shelf 20 below the individual plungers 90. The containers 22 are partially stoppered as shown in
Once the vessel 12 is fully pressurized and the temperature and pressure conditions therein have reached desired stabilized levels for the antisolvent employed, the device 14 is actuated in order to generate ultrasonic energy waves within the antisolvent in chamber 12. These waves propagate throughout the interior of the chamber and pass into the individual containers 22 past the loosely-fitted stoppers 82. This effects intense mixing of the antisolvent and the solution or dispersion within each of the containers 20 so that the solutions or dispersions become supersaturated and the solute or dispersant is selectively extracted into the antisolvent. This effects precipitation of the material within the containers. The precipitated material may be in various forms, including small particles in crystalline form or non-crystalline form, and an amorphous mass. If auxiliary ingredients are used, these generally precipitate along with the active ingredient. During this step, temperature and pressure conditions are carefully maintained so as to eliminate the possibility of overflow of the liquid from the containers 22 with consequent loss of material.
After the material has fully precipitated, the device 14 is left running for a period of 60-90 minutes with flowing antisolvent through chamber 12 and venting via vent 68. This assures that all residual liquid solvent or dispersion medium is removed from the containers. Thereafter, the high-pressure antisolvent is drained from the chamber 12 through vent 68 and the vessel is cooled to ambient. At this point, the stoppering apparatus 24 is employed to fully stopper each of the valves 82 (
The following examples set forth preferred techniques for the precipitation of particles of material in accordance with the invention. It is to be understood, however, that these examples are provided by way of illustration and nothing therein should be taken as a limitation upon the overall scope of the invention.
In Examples 1-3 below, the lyophobic precipitation of acetaminophen, ibuprofen, hydrocortisone, phenyloin, and insulin using supercritical CO2 antisolvent and ultrasonic energy was investigated using apparatus of the type illustrated in
The precipitation apparatus 10 included a high-pressure 6 L chamber 12 along with an ultrasonic transducer device 14 attached to the top inside of the chamber. Two view windows were provided in the chamber walls to allow visual inspection of the process. A platform 20, sized to hold up to 10 small containers 22, was located in the bottom of the chamber at approximately the base of the viewing windows. A 4.5 L surge tank 54 was used to control the fluctuation of CO2 flow from the CO2 pump 46, and a moisture trap 38 with desiccant was used to keep moisture out of the system. The maximum allowable pressure for the system was about 2,000 psi at a temperature of up to about 70° C.
In a typical lyophilization experiment, a number of containers 22, each containing a drug in solution, were loaded onto the platform 20 within chamber 12. The chamber was heated to a given temperature, and the entire system was tested for leakage using nitrogen gas test system 18. LabView program software was used to monitor and record the temperatures and pressures during the lyophilization/precipitation process.
After the nitrogen leak test, the chamber 12 was pressurized to a given pressure with CO2. When the specified temperature and pressure set points were attained and stabilized, the ultrasonic transducer device 14 was powered to effect intense mixing of the drug solution with CO2 within the containers 22. The pressure, temperature and ultrasonic energy were monitored to avoid overflow of the expanded drug solutions from the containers. It was found that preferred pressure and temperature values could be determined based upon the particular solvent used in the system. Once the drug was observed to precipitate and the solvent was extracted into the dense CO2 phase, the system parameters (ultrasonic energy, temperature, pressure, CO2 flow) were maintained for an additional 60-90 minutes to remove residual solvent from the containers. Preferably, the chamber 12 was then flushed with additional CO2 to remove the evaporated solvent, and to effect drying of any residual solvent from the drug. The chamber 12 was then carefully depressurized and the containers containing the precipitated drugs were retrieved and cooled to ambient temperatures. Specific experimental parameters are given below.
Drug solutions of varying concentrations in ethanol were prepared according to the table below.
2 mL of each test solution were transferred into a container. The containers were transferred to the platform inside the chamber. The chamber was then pressurized to 1200 psi using CO2, and the chamber was heated to about 62-66° C. to establish supercritical conditions. The ultrasonic transducer was then powered to about 15-70% power for about 38 minutes, during which time the drug was observed to precipitate. The power was maintained at about 50% for an additional 52 minutes to remove residual ethanol from the drug. The results are shown below.
From this experiment, it was determined that drying time of a drug solution is only slightly related to the drug concentration, if at all.
Drug solutions of varying concentrations in ethanol, or hexafluoro-2-proponal (HFIP), were prepared according to the table below.
Varying amounts of each drug solution according to the table above were transferred to designated containers. The containers were then placed on the platform in the chamber. The chamber was pressurized to 1,200 psi using CO2, and the chamber was heated to about 50° C. to establish supercritical conditions. The ultrasonic transducer was powered to about 15-40% power for about 60 minutes during which time the drug was observed to precipitate and the solvent evaporated into the CO2. The power was maintained at about 40-50% for an additional 90 minutes to remove residual solvent from the drug until dry. The results are shown below.
From this experiment, it was determined that insulin is easily expanded, and some precipitation was observed even before the ultrasonic transducer was turned on. The acetaminophen was observed to precipitate as crystals and the phenyloin was observed to precipitate as needle-shaped crystals.
Drug solutions of varying concentrations in ethanol or HFIP were prepared according to the table below.
Varying amounts of each drug solution according to the table above were transferred to designated containers. The containers were transferred onto the platform in the chamber. The chamber was pressurized to 1,200 psi using CO2, and the vessel was heated to about 50° C. to establish supercritical conditions. The ultrasonic generator was programmed to be on for 1 second, off for 2 seconds, and the power supply was incrementally increased until the drug was fully precipitated, and the solvent evaporated. The power supply was at 15% for about 10 minutes, increased to 20% for about 65 minutes, increased to 24% for about 35 minutes, increased to 28% for about 40 minutes and finally increased to 30% for about 185 minutes, for a total of 5 hours and 30 minutes to complete the process. The power was then maintained at about 40% for an additional 50 minutes to remove residual solvent from the drug until dry. The results are shown below.
The precipitated drug particles from this experiment were observed to be larger in size than particles produced in the previous two experiments. Insulin, in particular, was observed to be much larger as precipitated in experiment three, than in experiment two. From this it was concluded that processing time correlates with particle size. Thus, shorter processing time results in smaller drug particle size.
From the following example, the significant advantages of the present invention over conventional mechanical mixing are illustrated.
In this experiment, an air-actuated shaker was employed in an attempt to effect lyophobic precipitation in a supercritical CO2 environment via mechanical mixing. A platform was located in the high-pressure chamber at approximately the base of the viewing windows and the containers containing the drug solution were placed on the platform. Compressed air was used to shake the platform in a horizontal plane such that the contents of the container were swirled without being spilled due to motion.
Two containers were each filled separately with 1 mL of a saturated drug solution and placed on the mixing platform in the vessel. The first container contained phenyloin in acetone and the second container contained hydrocortisone in acetone. The temperature of the vessel was varied between 36 and 63° C. and the vessel was pressurized with CO2 to near/supercritical, about 910-1,220 psi. The shaking time required to precipitate the drugs was up to forty-four (44) hours.
The initial experiment showed that the level of saturated solution of drug and acetone stayed virtually the same even after mechanical shaking for about 4-5 hours. While a clear meniscus was observed between the CO2 and the drug solution at higher temperatures of about 48-63° C., no clear meniscus was observed at the lower temperatures of about 36-42° C. However, even after about 42-44 h, only 1 mL of the solvent had evaporated, even at higher temperatures.
From this it was concluded that the drug solution/CO2 interface could not be sufficiently disturbed by the mechanical shaking to cause intense mixing between the two phases, and that severe transport limitations exist for solvent diffusion into the CO2 phase.
| Number | Date | Country | |
|---|---|---|---|
| 60829082 | Oct 2006 | US |
